Thrombocytopenia is one of the side effects of VPA. This study aimed to evaluate the incidence and risk factors of thrombocytopenia after intravenous VPA treatment in children with neurosurgical operations. Pediatric patients undergoing neurosurgical operations treated with intravenous VPA were enrolled in this retrospective study. According to platelet count after intravenous injection of VPA, the pediatric patients were divided into the thrombocytopenia group and the non-thrombocytopenia group. Binary logistic regression analysis was used to explore the risk factors for thrombocytopenia. A total of 252 children with neurosurgical operations were included in this study, and the incidence of thrombocytopenia was 12.3% (31/252). Univariate analysis showed that baseline platelet count, duration of VPA therapy, and blood loss were associated with the occurrence of thrombocytopenia after intravenous administration of VPA. Binary logistic regression revealed that baseline platelet count (OR 0.995, 95% CI 0.991–0.999) and blood loss (OR 0.995, 95% CI 0.991–0.999) were independent risk factors for thrombocytopenia after intravenous VPA in children undergoing neurosurgical operations. Our data show that thrombocytopenia is common in neurosurgical operations children treated with intravenous VPA, and that baseline platelet count is an independent risk factor for thrombocytopenia. Regular monitoring of baseline platelet count is important for whether to short-term prophylactic use intravenous VPA in children undergoing neurosurgical operations.
Background and objectives: Lacosamide (LCM) is a third-generation concomitant antiseizure medication (ASM) that is widely used in epilepsy treatment. Reported data on the predictors of efficacy of LCM in children with epilepsy are scarce. This study aimed to explore the predictors of LCM efficacy in pediatric patients with epilepsy. Methods: This single-center retrospective cohort study was conducted in China, consecutively enrolled pediatric epilepsy patients receiving lacosamide treatment; the study period for data collection was September 2021 to April 2025. Demographic data, LCM daily dose, serum concentration, concentration-to-dose ratio (CDR), ASMs, and seizure frequency before and after treatment were collected. Patients were categorized into effective (≥50% seizure reduction) and ineffective groups. Univariate analysis and ridge regression were used to assess the impact of the factors on the efficacy of LCM. The receiver operating characteristic (ROC) curve was used to evaluate the predictive performance of the ridge regression model. Results: A total of 71 children with epilepsy were enrolled in this study (boys: 35, 49.3%; girls: 36, 50.7%). The overall effectiveness rate was 81.69%. Univariate analysis showed a significantly higher CDR in the effective group compared to the ineffective group (0.768 vs. 0.58, P = 0.031). In this exploratory pilot analysis, ridge regression implied that CDR has a positive effect on the efficacy of LCM. The AUC of the predictive performance of the ridge regression model was 0.767 (95% CI: 0.651–0.875). Discussion: CDR, reflecting weight- and dose-adjusted LCM exposure, is a predictor of LCM efficacy in pediatric epilepsy. These findings support the use of CDR for guiding individualized LCM therapy. Further multicenter studies with larger samples are warranted to validate these results and establish an optimal CDR range.